Atlas Venture completes ‘disciplined’ $450 million fundraise

Atlas Venture, one of the leading venture capital firms in the biotech industry, has raised $450 million for a new fund, the firm’s leaders told STAT exclusively.

The fund — Atlas’ 14th — will go towards seed and series A rounds for biotech companies, most of which the firm will have a hand in creating. Atlas rarely takes outside pitches from entrepreneurs, though it will sometimes team up with other VC firms that have launched a new startup.

The news comes just a few weeks after Partner Bruce Booth mentioned that the firm was raising the fund during his annual “year-in-review” video presentation.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Canine transmission models provide insights into the neurological impacts of COVID-19 on human brains

The histopathologic alteration caused by SARS‑CoV‑2 on mammalian neurological systems.

October 20, 2023

Hallucinogen use linked to increased risk of mortality in emergency care patients

People seeking emergency care for hallucinogen use were at 2.6-fold higher risk of death within 5 years than the general population, according to a new

March 3, 2025

Novartis snaps up rare disease biotech DTx Pharma in $1bn deal –

DTx Pharma’s Charcot-Marie-Tooth therapy candidate was able to induce remyelination of axons. Axons in patients with type 1 of the disease have myelin abnormalities. Image

July 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.